News

MIN-202 is being developed by Minerva Neurosciences in collaboration with Janssen Pharmaceutica and Janssen Research & Development. The completion of the IND review will allow Janssen to start

In March this year, NovaDel announced its plans to sell all assets with the intention of liquidating the company and distributing its remaining cash to shareholders. With the

The study demonstrating that topical application of pterostilbene onto mouse skin, prior to UV exposure, prevented several types of UV-mediated damage. Specifically, pterostilbene prevented UV-mediated DNA damage, reddening

This multi-centre, placebo-controlled clinical trial (Protocol TRx-237-005) is aimed at assessing the efficacy of LMTX in people diagnosed with mild Alzheimer’s disease. The study is also evaluating the

Concurrently, the Company announced a new corporate management team and its intention to strategically refocus and rebrand the company as PlasmaTech Biopharmaceuticals, Inc.™, and its plans to pursue

With an ED market that brings in billions annually, it’s not hard to figure out why Plandaí would use its unique and proprietary extraction process to try to

Clinical Ink’s SureSource will replace paper scales with fully electronic questionnaires incorporating built-in logic, automated scoring, and integrated audio recordings to improve the assessment of critical efficacy endpoints.

Under the deal, Merck will acquire all of Sigma-Aldrich for $140 a share in cash, a 37% premium to Sigma’s latest closing price of $102.37. The acquisition is

Pathologic myopia and the associated myopic CNV is the second most common cause of blindness, in this country. Eylea approval is based on positive data from the Phase